NASDAQ:CSTL
Castle Biosciences, Inc. Stock News
$24.24
+0.0200 (+0.0826%)
At Close: May 17, 2024
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL--Castle Biosciences today announced the closing of its previously announced underwritten public offering.
Castle Biosciences Announces Pricing of $232 Million Public Offering of Common Stock
08:01pm, Tuesday, 15'th Dec 2020
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL--Castle Biosciences announced today the pricing of its underwritten public offering.
Castle Biosciences Announces Commencement of Proposed Public Offering of Common Stock
04:45pm, Monday, 14'th Dec 2020
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL--Castle announced today that it has commenced a proposed underwritten public offering.
Castle Biosciences Announces Publication of Peer-Reviewed Publication Demonstrating the Clinical Impact of DecisionDx®-Melanoma
07:00am, Friday, 04'th Dec 2020
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #castlebiosciences--Castle Biosciences Announces Publication of Peer-Reviewed Publication Demonstrating the Clinical Impact of DecisionDx®-Melanoma
Castle Biosciences to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference
05:00pm, Monday, 23'rd Nov 2020
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #cancerdiagnostics--Castle Biosciences to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #castlebiosciences--Castle Biosciences Announces Publication of Clinical Validation and Utility Data for DecisionDx® DiffDx™-Melanoma for Suspicious Pi
Castle Biosciences, Inc. (CSTL) CEO Derek Maetzold on Q3 2020 Results - Earnings Call Transcript
11:57pm, Monday, 09'th Nov 2020
Castle Biosciences, Inc. (CSTL) CEO Derek Maetzold on Q3 2020 Results - Earnings Call Transcript
Melanoma Research Alliance Announces 13 Dermatology Fellowship Awards
12:00am, Thursday, 08'th Oct 2020
The Melanoma Research Alliance, the largest non-profit funder of melanoma research, has named 13 promising clinicians/researchers-in-training as 2020
Oct 01, 2020 (The Expresswire) --
“Melanoma Therapeutics Market" report provides a detailed evaluation of the market by highlighting information on different...
Oct 01, 2020 (The Expresswire) --
Global "Melanoma Therapeutics Market" 2020 report includes the market strategy, market orientation, expertise opinion and...
Oct 01, 2020 (The Expresswire) --
Global "Melanoma Therapeutics Market" 2020 report includes the market strategy, market orientation, expertise opinion and...
Oct 01, 2020 (The Expresswire) --
Global "Melanoma Therapeutics Market" 2020 report includes the market strategy, market orientation, expertise opinion and...
TriSalus Life Sciences Lays Out Therapeutic Strategy Upon Acquisition of First Therapeutic Candidate
12:00am, Thursday, 24'th Sep 2020
TriSalus Life Sciences announces its therapeutic clinical development strategy following the acquisition of SD-101, from Dynavax Technologies.
Everbridge, Inc. (NASDAQ: EVBG), the global leader in critical event management (CEM), today announced approval for the latest version of its next-gen
